Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.
Clinical Trials
8
4 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
4
50.0%
Completed
4
50.0%
No approval data available
- Hepion Pharmaceuticals has in-licensed a novel circulating tumor RNA (ctRNA) biomarker assay from Cirna Diagnostics to facilitate early diagnosis of hepatocellular carcinoma in high-risk patients with cirrhosis. - The next-generation liquid biopsy platform detects cancer-specific mutant RNA variants in blood and offers improved specificity compared to DNA-based approaches, with potential applications across multiple solid tumor types. - Current HCC surveillance methods miss up to 75% of early-stage cancers, representing a significant unmet medical need that this technology aims to address. - The licensing agreement complements Hepion's recently acquired mSEPT9 PCR-based assay and reflects the company's strategic shift toward advancing clinically proven liquid biopsy tests under new leadership.
- Researchers at King's College London demonstrated that cyclophilin inhibitors can reverse key features of alcohol-related liver disease by reducing fibrotic protein accumulation in human tissue models. - The study used precision-cut liver slices and isolated hepatic stellate cells from human liver tissue to show the drug's ability to alter tissue structure and reduce fibrogenic activity. - These findings provide new mechanistic insights into cyclophilin inhibitors' therapeutic potential for treating alcohol-related liver fibrosis, a condition with no currently approved medical therapies. - The use of human-derived 3D models offers high clinical relevance compared to traditional animal studies, potentially accelerating translation to clinical applications.
